Fluoxetine in Pediatric Body Dysmorphic Disorder

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial will study the effectiveness of the medication fluoxetine for children and adolescents ages 16 and younger with BDD who qualify.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Montefiore Medical Center
• Collaborator: Food and Drug Administration (FDA)
• Treatments: Fluoxetine

Criteria

Inclusion Criteria:

• Male or female children and adolescents aged 16 and younger

• BDD or its delusional variant present currently and for at least 6 months prior to the study

• Ability to communicate meaningfully with the investigators and competent to provide written assent

Exclusion Criteria:

• Presence of Schizophrenia or Bipolar Disorder

• Recent suicide attempt or suicidal ideations that warrant hospitalizations

• Previous allergic reaction to fluoxetine

• History of a seizure disorder